2019 Keystone Symposium: Why so many ways to die? Apoptosis, necroptosis, pyroptosis, and beyond
Time & Location
About the Event
Cell Death is linked to diverse physiological and pathological conditions. A recent Keystone Symposium on Cell Death happened in Guarujá, São Paulo, Brazil, from November 19–24, 2019. The first (2010) and second (2014) successful Meetings in the cell death field opened the doors to scientific update in 2019. The third Meeting on cell death “Why so many ways to die? Apoptosis, necroptosis, pyroptosis and beyond” was organized by Karina R. Bortoluci, Andreas Strasser, and Vishva M. Dixit. Over 150 scientists from all continents, including ones from industry, healthcare professionals as well as principal investigators, postdocs, and graduate students from academia shared 5 days of intense scientific discussions and data exchange.
The Meeting happened at a particularly important moment in the field with the recent discoveries of key regulators and effectors of cell death processes and, importantly, the first drug based on cell death research, the BCL-2 inhibitor venetoclax, now being used routinely in the clinic for the treatment of certain hematological cancers. The excellent talks from prominent more experienced and young scientists were instrumental to improve our understanding of the crosstalk among distinct cell death pathways in health and disease. A fantastic and friendly atmosphere was present during the workshops, short talks, and poster sections, allowing new insights and prospects during discussions.
This Meeting was a milestone on cell death research. Novel mechanisms of action of crucial constituents of the machineries of several cell death pathways, such as caspase- 8 and GSDMD, were presented for the first time in public. We learned that cell death is a highly dynamic process with extensive plasticity. Therefore, manipulating one type of cell death can often result in the induction of another type of cell death and this may have notable pathophysiological consequences for the organisms. Future challenges are to develop novel therapeutic interventions, which must probably rely on targeting multiple molecules/cell death pathways in the treatment of inflammatory diseases, cancer and infectious diseases.